169 related articles for article (PubMed ID: 34093808)
1. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma.
Liu F; Hou W; Liang J; Zhu L; Luo C
J Cancer; 2021; 12(13):4039-4048. PubMed ID: 34093808
[TBL] [Abstract][Full Text] [Related]
2. LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.
Cheng Y; Tang R; Li X; Wang B; Cheng Y; Xiao S; Sun P; Yu W; Li C; Lin X; Zhu Y
J Hepatocell Carcinoma; 2022; 9():203-220. PubMed ID: 35345553
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
[TBL] [Abstract][Full Text] [Related]
4.
Wang L; Yan K; He X; Zhu H; Song J; Chen S; Cai S; Zhao Y; Wang L
J Cancer; 2021; 12(1):217-223. PubMed ID: 33391418
[No Abstract] [Full Text] [Related]
5. Correlation between
Hu S; Zhao X; Qian F; Jin C; Hou K
Comput Math Methods Med; 2021; 2021():1522250. PubMed ID: 34603481
[TBL] [Abstract][Full Text] [Related]
6. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma.
Wang M; Xiong Z
Int J Gen Med; 2021; 14():6343-6358. PubMed ID: 34629898
[TBL] [Abstract][Full Text] [Related]
7. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.
Yu G; Mu H; Fang F; Zhou H; Li H; Wu Q; Xiong Q; Cui Y
Medicine (Baltimore); 2022 Jul; 101(26):e29763. PubMed ID: 35777027
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway.
Zhen Z; Shen Z; Sun P
Bioengineered; 2022 Apr; 13(4):9467-9481. PubMed ID: 35389768
[TBL] [Abstract][Full Text] [Related]
9. Association of
Chen H; Chong W; Wu Q; Yao Y; Mao M; Wang X
Front Immunol; 2019; 10():1113. PubMed ID: 31164891
[No Abstract] [Full Text] [Related]
10. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
11. Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining.
Zhou W; Fang D; He Y; Wei J
J Gastrointest Oncol; 2021 Jun; 12(3):1117-1131. PubMed ID: 34295561
[TBL] [Abstract][Full Text] [Related]
12. HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma.
Xu Y; Huang Z; Yu X; Li Z; Zheng L; Xu J
Biologics; 2021; 15():329-341. PubMed ID: 34413629
[TBL] [Abstract][Full Text] [Related]
13. Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma.
Li M; Hu J; Jin R; Cheng H; Chen H; Li L; Guo K
J Hepatocell Carcinoma; 2020; 7():361-376. PubMed ID: 33324588
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment.
Luo M; Lin Y; Liang R; Li Y; Ge L
J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.
Liu B; Dong Z; Lu Y; Ma J; Ma Z; Wang H
Evid Based Complement Alternat Med; 2022; 2022():3478861. PubMed ID: 36034941
[TBL] [Abstract][Full Text] [Related]
16. High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.
Niu Y; Wang W; Jiang X; Huang Y; Yan S; Jiang Y
Jpn J Clin Oncol; 2022 Jul; 52(7):759-765. PubMed ID: 35348687
[TBL] [Abstract][Full Text] [Related]
17. Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response.
Hao F; Ma Q; Zhong D
Transl Oncol; 2022 Oct; 24():101493. PubMed ID: 35905642
[TBL] [Abstract][Full Text] [Related]
18. ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma.
Liu F; Liang J; Long P; Zhu L; Hou W; Wu X; Luo C
Front Oncol; 2021; 11():799566. PubMed ID: 35071004
[TBL] [Abstract][Full Text] [Related]
19. LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance.
Zhai X; Xia Z; Du G; Zhang X; Xia T; Ma D; Li X; Jin B; Zhang H
Genes Dis; 2023 Sep; 10(5):2082-2096. PubMed ID: 37492741
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Wang Z; Li N; Qi Z; Zhao J; Huang W
Cancer Cell Int; 2021 Jul; 21(1):342. PubMed ID: 34217320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
